Friday’s Midday Movers: American Green Inc (ERBB), Halcon Resources (HK), Can-Fite BioPharma (CANF), Palatin Technologies (PTN), Achillion Pharmaceuticals (ACHN)

By Carrie Williams

So far Friday, May 17, NASDAQ is up 1.19% and the S&P is up 2.61%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; American Green Inc (ERBBResearch Report), Halcon Resources (HKResearch Report), Can-Fite BioPharma (CANFResearch Report), Palatin Technologies (PTNResearch Report) and Achillion Pharmaceuticals (ACHNResearch Report).

American Green Inc is down -33.33% in midday trading to $0.00. Shares opened today at $0.00. The company has a 52-week low of $0.00 and a 52-week high of $0.00.

Halcon Resources is down -15.02% in midday trading to $0.22. Shares opened today at $0.25. The company has a 52-week low of $0.21 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $4.00, marking a 1481.03% potential upside from current levels. In a report issued on May 13, Imperial analyst Jason Wangler maintained a Hold rating on HK, with a price target of $1, which implies an upside of 295% from current levels.

Can-Fite BioPharma is down -11.74% in midday trading to $5.11. Shares opened today at $5.79. The company has a 52-week low of $5.11 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $30.00, marking a 418.13% potential upside from current levels. In a report issued on May 9, H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on CANF, with a price target of $30, which implies an upside of 418% from current levels.

See today’s analyst top recommended stocks >>

Palatin Technologies is down -11.34% in midday trading to $1.53. Shares opened today at $1.72. The company has a 52-week low of $0.59 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $4.38, marking a 154.65% potential upside from current levels. In a report issued on May 10, Ladenburg Thalmann analyst Michael Higgins maintained a Buy rating on PTN, with a price target of $2.75, which implies an upside of 60% from current levels.

Achillion Pharmaceuticals is down -10.76% in midday trading to $2.87. Shares opened today at $3.22. The company has a 52-week low of $1.29 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $4.25, marking a 31.99% potential upside from current levels. In a report issued on May 3, Barclays analyst Geoff Meacham downgraded ACHN to Sell, with a price target of $2.50, which implies a downside of 22% from current levels. Separately, on March 8, JMP’s Liisa Bayko reiterated a Buy rating on the stock and has a price target of $6.

Trending Stocks Based on Insider Activity >>